Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Antonio Ciardi  (Ciardi A) 1 Article
Clinical Study
Subclinical Atherosclerosis in Patients with Cushing Syndrome: Evaluation with Carotid Intima-Media Thickness and Ankle-Brachial Index
Luigi Petramala, D'Elia Lorenzo, Gino Iannucci, Antonio Concistré, Laura Zinnamosca, Cristiano Marinelli, Giuseppe De Vincentis, Antonio Ciardi, Giorgio De Toma, Claudio Letizia
Endocrinol Metab. 2015;30(4):488-493.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.488
  • 2,673 View
  • 36 Download
  • 6 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM
Background

Cushing syndrome (CS) has been described as a killing disease due its cardiovascular complications. In fact, chronic cortisol excess leads to a constellation of complications, including hypertension, hyperglycemia, adiposity, and thromboembolism. The main vascular alteration associated with CS is atherosclerosis.

Methods

Aim of this study was to analyze carotid intima-media thickness (cIMT) and ankle-brachial index (ABI), two surrogate markers of subclinical atherosclerosis in a consecutive series of CS patients, compared to patients with essential hypertension (EH) and health subjects (HS).

Results

Patients with CS showed a significant increase (P<0.05) of cIMT (0.89±0.17 mm) compared to EH (0.81±0.16 mm) and HS (0.75±0.4 mm), with a high prevalence of plaque (23%; P<0.03). Moreover, CS patients showed a mean ABI values (1.07±0.02) significantly lower respect to HS (1.12±0.11; P<0.05), and a higher percentage (20%) of pathological values of ABI (≤0.9; P<0.03).

Conclusion

In conclusion, we confirmed and extended the data of cIMT in CS, and showed that the ABI represent another surrogate marker of subclinical atherosclerosis in this disease.

Citations

Citations to this article as recorded by  
  • Capillary microarchitectural changes in Cushing's syndrome
    Tugce Apaydin, Yasemin Yalcinkaya, Can Ilgin, Dilek Gogas Yavuz
    Microvascular Research.2022; 141: 104323.     CrossRef
  • Glucocorticoid therapy is a risk factor for cardiovascular diseases
    I. S. Dzherieva, N. I. Volkova, I. Y. Davidenko, I. B. Reshetnikov, S. S. Brovkina, S. M. Avakova, Y. V. Tishchenko
    Medical Herald of the South of Russia.2022; 13(3): 93.     CrossRef
  • Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers?
    Clare MacLeod, Patrick W. F. Hadoke, Mark Nixon
    International Journal of Molecular Sciences.2021; 22(14): 7622.     CrossRef
  • Cardiovascular and metabolic risk factors in patients with subclinical Cushing
    Luigi Petramala, Federica Olmati, Antonio Concistrè, Riccardo Russo, Martina Mezzadri, Maurizio Soldini, Giuseppe De Vincentis, Gino Iannucci, Giorgio De Toma, Claudio Letizia
    Endocrine.2020; 70(1): 150.     CrossRef
  • Should Cushing's Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?
    Goran Koracevic, Milan Stojkovic, Dragan Lovic, Milan Pavlovic, Tomislav Kostic, Marija Kutlesic, Sladjana Micic, Maja Koracevic, Milan Djordjevic
    Current Vascular Pharmacology.2019; 18(1): 12.     CrossRef
  • Markers of atherosclerosis in patients with Cushing’s syndrome: a meta-analysis of literature studies
    Roberta Lupoli, Pasquale Ambrosino, Anna Tortora, Livia Barba, Gelsy Arianna Lupoli, Matteo Nicola Dario Di Minno
    Annals of Medicine.2017; 49(3): 206.     CrossRef

Endocrinol Metab : Endocrinology and Metabolism